News

Scotland’s approval of PrEP creates postcode lottery in UK, say campaigners

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1834 (Published 11 April 2017) Cite this as: BMJ 2017;357:j1834
  1. Bryan Christie
  1. Edinburgh

Demand is mounting for UK-wide access to pre-exposure prophylaxis (PrEP) to help prevent the transmission of HIV, after it was approved for use on the NHS in Scotland.

Campaigners welcomed the Scottish Medicines Consortium’s (SMC) decision to make Scotland the first part of the UK to approve emtricitabine/tenofovir disoproxil (Truvada) for use on a preventive basis by people without HIV.

PrEP has been shown to be 86% effective in preventing transmission if taken as prescribed and is currently available in Canada, France, Kenya, Norway, and the US. Preventing infection can save an estimated £360 000 (€422 000; $447 000) a patient, which is the …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe